Lyprinol® is a unique all-natural anti-inflammatory that has a multi-targeted action on several pathways of excessive inflammation.

Supercritical fluid extracts of New Zealand green-lipped mussels (NZGLM) have been suggested to have therapeutic properties related to their oil components. The large number of minor FA in NZGLM extract was characterized by a GC–CIMS/MS method that excels at identification of doublebond positions in FAME. The extract contained five major lipid classes: sterol esters, TAG, FFA, sterols, and polar lipids. The total FA content of the lipid extract was 0.664 g/mL. Fifty-three unsaturated FA (UFA) were fully identified, of which 26 were PUFA, and a further 21 UFA were detected for which concentrations were too low for assignment of double-bond positions. There were 17 saturated FA, with 14:0, 16:0, and 18:0 present in the greatest concentration. The ten n-3 PUFA detected included 20:5n-3 and 22:6n-3, the two main n-3 FA; n-3 PUFA at low concentration were 18:3, 18:4, 20:3, 20:4, 21:5, 22:5, 24:6, and 28:8. There were 43 UFA from the n-4, n-5, n-6, n-7, n-9, and n-10 families, with 16:2n-4, 16:1n-5, 18:1n-5, 18:2n- 6, 20:4n-6, 16:1n-7, 20:1n-7, 16:1n-9, 18:1n-9, and 20:1n-9 being the most abundant. In general, we estimated that FAME concentrations greater than 0.05% (w/w) were sufficient to assign double-bond position. In total, 91 FA were detected in an extract of the NZGLM, whereas previous studies of fresh flesh from the NZGLM had reported identification of 42 FA. These data demonstrate a remarkable diversity of NZGLM FA. Paper no. L9596 in Lipids 40, xxx–xxx (April 2005).

The aim of the study was to determine if Lyprinol® is effective in reducing pain, indicators of inflammation and muscle damage, and in turn improving performance in well trained athletes suffering from delayed onset muscle soreness (DOMS). Design: A double blind randomised placebo controlled trial.

The present study has identified in the marine mollusc, Perna canaliculus, an homologous series of novel omega 3 polyunsaturated fatty acids (ω-3 PUFA) with significant anti-inflammatory (AI) activity. The free fatty acid (FFA) class was isolated from a supercritical-CO2 lipid extract of the tartaric acid-stabilised freeze-dried mussel powder by normal phase chromatography, followed by reversed-phase high performance liquid chromatography (RP–HPLC). The RP–HPLC involved separation based on carbon numbers, followed by argentation–HPLC (Ag–HPLC) of the methyl esters based on degree of unsaturation. Identification of the FFA components was performed using gas chromatography (GC) with flame ionisation detection, and individual structures were assigned by GC-mass spectroscopy (GC-MS). Inhibition of leukotriene production by stimulated human neutrophils was used as an in vitro screening method to test the AI activity of the purified PUFAs. A structurally related family of ω-3 PUFAs was identified in the most bioactive fractions, which included C18:4, C19:4, C20:4, and C21:5 PUFA. The C20:4 was the predominant PUFA in the extract, and was a structural isomer of arachidonic acid (AA). The novel compounds may be biologically significant as AI agents, as a result of their in vitro inhibition of lipoxygenase products of the AA pathway.

The Stabilised lipid oil from the New Zealand Green Lipped Mussel (Lyprinol®) and Fish oil; are considered beneficial for the treatment of inflammatory conditions including asthma and arthritis. Sports medicine practitioners often witness the occurrence of Exercise Induced Bronchoconstriction (EIB). This condition is thought to be due to the flow of air in a lung pipe (with living cells bordering it) whereby these cells react and release variable amounts of inflammatory mediators, as "protection". We were interested in understanding why we observed better lung efficiency in endurance athletes using Lyprinol®. In Germany, the largest group of purchasers of Lyprinol® are endurance athletes. It is hypothesised that Lyprinol’s anti- inflammatory action helps increase the air flow by protecting the airways against inflammatory mediators. This is particularly observable for athletes undergoing extreme exercise. In order to learn if Lyprinol® does improve lung function for athletes, we have monitored the lung capacity of a small group of sub elite athletes and found that uploading of Lyprinol® resulted in increases in lung capacity. To better understand this phenomenon, we have also searched the literature on Exercise Induced Bronchoconstriction and Asthma.

The effect of Lyprinol was evaluated on LTB₄-induced human monocytes (normal and allergic donors) activation. Peripheral blood normal monocyte-derived monocytes when stimulated by Interleukin-4 (IL-4) produced high amounts of leukotriene B₄ (LTB₄) through the activation of the 5-lipoxygenase pathway. Maximal effect was observed in the presence of 10 ng/ml IL-4, and maximal LTB₄ production was reached 40 minutes after the onset of stimulation.

Live cold-adapted reassortant influenza vaccine (LAIV) is an effective means of controlling influenza among children, adults and elderly [1-3]. In comparison with inactivated influenza vaccines, LAIV has the advantages of stimulating the mucosal as well as cellular immune responses whereas it is slightly less effective in stimulating the serum antibody responses [4]. The possibility of using Lyprinol to raise serum antibody as well as cellular immune responses in human after vaccination with live attenuated influenza vaccine were studied.

Runners are prone to delayed onset muscle soreness (DOMS) during long distance training. This especially holds for unaccustomed training volumes at moderate to high intensities. We investigated the effects of a marine oil complex, PCSO-524®, derived from the New Zealand green-lipped mussel (formulated as Lyprinol® and Omega XL®) on DOMS after a 30 km training run.